JEFFERIES praises Dermapharm for ‘Buy’

NEW YORK (dpa-AFX Analyser) – Jefferies’ analysis house has placed the purchase for Dermapharm on “Buy” with a price of 51 euros. The end of the research in the second quarter would play a major role in the analysis of analyst Fabian Piasta in one of his service researches after the preparation of Mitte August. The separate factor is an analysis of a Verbesserung der Wirtschaftslage in Frankreich, one of the many years that the market brings a new product to the market./lfi/ngu

Veröffentlichung der Original-Studie: 27.08.2024 / 02:17 / ET
First publication of the original study: 27.08.2024 / 02:17 / ET

Note: Information about Offenlegungspflicht bei Interessenkonflikten im Sinne von § 85 Abs. 1 WpHG, art. 20 VO (EU) 596/2014 for the generated analyst house can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.

The Dermapharm Holding Aktie is selling a product with a drawback -0.43 % and a course of 34.60EUR traded on Tradegate (27 August 2024, 10:07 am).